Article

Two-Year Neurodevelopmental Outcomes of Ventilated Preterm Infants Treated with Inhaled Nitric Oxide

Case Western Reserve University, Cleveland, OH, USA.
The Journal of pediatrics (Impact Factor: 3.74). 02/2010; 156(4):556-61.e1. DOI: 10.1016/j.jpeds.2009.10.011
Source: PubMed

ABSTRACT In a randomized multi-center trial, we demonstrated that inhaled nitric oxide begun between 7 and 21 days and given for 24 days significantly increased survival without bronchopulmonary dysplasia (BPD) in ventilated premature infants weighing <1250 g. Because some preventative BPD treatments are associated with neurodevelopmental impairment, we designed a follow-up study to assess the safety of nitric oxide.
Our hypothesis was that inhaled nitric oxide would not increase neurodevelopmental impairment compared with placebo. We prospectively evaluated neurodevelopmental and growth outcomes at 24 months postmenstrual age in 477 of 535 surviving infants (89%) enrolled in the trial.
In the treated group, 109 of 243 children (45%) had neurodevelopmental impairment (moderate or severe cerebral palsy, bilateral blindness, bilateral hearing loss, or score <70 on the Bayley Scales II), compared with 114 of 234 (49%) in the placebo group (relative risk, 0.92; 95% CI, 0.75-1.12; P = .39). No differences on any subcomponent of neurodevelopmental impairment or growth variables were found between inhaled nitric oxide or placebo.
Inhaled nitric oxide improved survival free of BPD, with no adverse neurodevelopmental effects at 2 years of age.

Full-text

Available from: Avital Cnaan, Apr 28, 2015
0 Followers
 · 
179 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Increasing numbers of preterm neonates survive with motor and cognitive disabilities related to less destructive forms of cerebral injury that still result in reduced cerebral growth. White matter injury results in myelination disturbances related to aberrant responses to death of pre-myelinating oligodendrocytes (preOLs). PreOLs are rapidly regenerated but fail to mature to myelinating cells. Although immature projection neurons are more resistant to hypoxia-ischemia than preOLs, they display widespread disturbances in dendritic arbor maturation, which provides an explanation for impaired cerebral growth. Thus, large numbers of cells fail to fully mature during a critical window in development of neural circuitry. These recently recognized forms of cerebral gray and white matter dysmaturation suggest new therapeutic directions centered on reversal of the processes that promote dysmaturation.
    Clinics in perinatology 03/2014; 41(1):1-24. DOI:10.1016/j.clp.2013.11.001 · 2.13 Impact Factor
  • Annals of Neurology 04/2014; 75(4). DOI:10.1002/ana.24132 · 11.91 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background:Surfactant dysfunction may contribute to the development of bronchopulmonary dysplasia in persistently ventilated preterm infants. We conducted a multicenter randomized, blinded pilot study to assess the safety and efficacy of late doses of a surfactant protein-B (SP-B) containing surfactant (calfactant) in combination with prolonged inhaled nitric oxide (iNO) in infants ≤ 1000g birth weight.Methods:We randomized 85 preterm infants ventilated at 7-14 d to late surfactant (up to 5 doses) and prolonged iNO versus iNO-alone. Large aggregate surfactant was isolated from daily tracheal aspirates for measurement of SP-B content, total protein and phospholipid.Results:Late surfactant was administered with minimal acute adverse effects. Clinical status and tracheal aspirate surfactant recovery and SP-B content were transiently improved compared to Controls; effects waned after 1 day. The change in SP-B content with surfactant dosing was positively correlated with SP-B levels during treatment (r=0.50, P=0.02).Conclusion:Low SP-B content increased with calfactant administration, but the relationship of response to SP-B levels suggests degradation as a contributing mechanism for SP-B deficiency and surfactant dysfunction. We conclude that late surfactant therapy in combination with iNO is safe and transiently increases surfactant SP-B content, which may lead to improved short- and long-term respiratory outcomes.Pediatric Research (2012); doi:10.1038/pr.2012.136.
    Pediatric Research 10/2012; 72(6). DOI:10.1038/pr.2012.136 · 2.84 Impact Factor